| 4644 |
Centers for Disease Control and Prevention |
Html |
en |
Conjunctivitis: Treatment |
The treatment for conjunctivitis depends on the cause. |
| allergic conjunctivitis | 0.462265 |
| Mild bacterial conjunctivitis | 0.592515 |
| certain eye drops | 0.333095 |
| cold compresses | 0.242448 |
| topical antihistamine | 0.226509 |
| artificial tears | 0.237374 |
| herpes simplex virus | 0.335841 |
| red eye | 0.219923 |
| viral conjunctivitis | 0.786656 |
| best treatment options | 0.315822 |
| antibiotic resistance | 0.241121 |
| prescription eye | 0.221183 |
| pink eye | 0.243657 |
| contact lenses | 0.233761 |
| eye drops | 0.339716 |
| Fam Physician. | 0.231905 |
| antibiotic treatment | 0.243323 |
|
| antiviral medication | 0.235201 |
| specific treatment | 0.226374 |
| Allergy medications | 0.217802 |
| Kankanala RR | 0.223069 |
| conjunctivitis | 0.927172 |
| medical care | 0.240413 |
| increased costs | 0.220695 |
| doctor | 0.27236 |
| Mauger T. Diagnosis | 0.331173 |
| eye doctor | 0.237638 |
| varicella-zoster virus | 0.23693 |
| animal dander | 0.21784 |
| healthcare provider | 0.234481 |
| bacterial conjunctivitis | 0.606385 |
| following cases | 0.221657 |
| primary care | 0.215496 |
| antibiotics | 0.25329 |
|
CLICK HERE |
| 5171 |
Centers for Disease Control and Prevention |
Html |
en |
Oregon Activities to Prevent HAIs |
null |
| MDROs | 0.419599 |
| Injection Safety | 0.680977 |
| HAI Data | 0.657735 |
| Healthcare-associated Infections | 0.529291 |
| HAI Detection | 0.700028 |
| email address | 0.661202 |
| CDI | 0.43419 |
| recent work | 0.663077 |
| Infection Prevention | 0.589376 |
| Clostridium difficile infection | 0.70975 |
| Appropriate Antibiotic | 0.557429 |
| Educational Efforts | 0.542209 |
| monthly update | 0.681353 |
|
| Coordinated Prevention | 0.562123 |
| Infection Control Assessment | 0.685866 |
| ELC HAI-funded Activities | 0.685659 |
| Enterobacteriaceae (CRE) | 0.681204 |
| Regional Multidrug-Resistant Organism | 0.635555 |
| infectious disease | 0.684571 |
| Antimicrobial Resistance | 0.552855 |
| Laboratory Capacity | 0.542902 |
| Initial Implementation | 0.52655 |
| information | 0.42213 |
| CLABSI Validation Guidance | 0.628019 |
| HAI Prevention Infrastructure | 0.961806 |
|
CLICK HERE |
| 6835 |
Centers for Disease Control and Prevention |
Html |
en |
Global Health - Dr. Frieden visits Kenya |
In Kenya, the CDC is addressing the region's toughest health problems at their source, directly working with vulnerable families and communities in local hospitals, clinics, and laboratories. |
| CDC | 0.860943 |
| CDC staff in-country | 0.737051 |
| foreign countries | 0.504232 |
| Secretary | 0.416234 |
| Laboratory Training Program | 0.590482 |
| demographic status | 0.500026 |
| polio eradication program | 0.631368 |
| U.S. efforts | 0.507961 |
| technical support | 0.494493 |
| Human Services Kathleen | 0.574685 |
| Institute | 0.416538 |
| CDC Field Research | 0.742024 |
| CDC-affiliated staff | 0.503964 |
| epicenter | 0.422002 |
| FETP/FELTP website | 0.503549 |
| laboratory training | 0.60351 |
| field station | 0.497222 |
| Dr. Tom Frieden | 0.76604 |
| disease surveillance | 0.492073 |
| Scott Gration | 0.513561 |
| important contributions | 0.490518 |
| officers | 0.417393 |
| important milestone | 0.495945 |
|
| CDC staff | 0.837726 |
| CDC overseas platforms | 0.731937 |
| laboratory training programs | 0.587926 |
| strategies | 0.417008 |
| Director | 0.418938 |
| polio case | 0.554838 |
| KEMRI | 0.449683 |
| CDC staff collect | 0.746551 |
| w/ largest gathering | 0.583937 |
| people | 0.416266 |
| Kenya Medical Research | 0.677329 |
| India | 0.458617 |
| global health activities | 0.619272 |
| dynamic public health | 0.599801 |
| TP programs | 0.510105 |
| U.S. Ambassador | 0.514785 |
| Kenyan health officials | 0.630129 |
| Kisian | 0.416621 |
| Field Epidemiology | 0.525074 |
| preventable deaths | 0.521142 |
| Learn | 0.416992 |
| information | 0.416316 |
| visit | 0.431013 |
|
CLICK HERE |
| 7267 |
Centers for Disease Control and Prevention |
Html |
en |
CDC Reports Cases 14-17 of H3N2v Infection; Shares Advice for Safe Fair-Going |
CDC Reports Cases 14-17 of H3N2v Infection; Shares Advice for Safe Fair-Going. |
| flu symptoms | 0.465207 |
| H3N2v infections | 0.49467 |
| infect swine | 0.718489 |
| fairs | 0.473029 |
| United States | 0.51438 |
| Dr. Dan Jernigan | 0.546604 |
| Prevent Disease | 0.48266 |
| health care provider | 0.759713 |
| influenza antiviral drugs | 0.706687 |
| swine influenza | 0.81218 |
| reported swine contact | 0.759146 |
| pandemic H1N1 virus | 0.695065 |
| H3N2v | 0.579202 |
| swine herds | 0.66656 |
| State Public Health | 0.491731 |
| certain people | 0.42773 |
| seasonal influenza viruses | 0.637756 |
| animal areas | 0.469727 |
| swine contact | 0.782125 |
| heart disease | 0.482442 |
| H3N2v virus | 0.518944 |
| Raise Pigs Need | 0.489607 |
| CDC Influenza Division | 0.643182 |
| close contact | 0.42029 |
|
| Health care providers | 0.474398 |
| ill swine | 0.668453 |
| preventive actions | 0.492629 |
| Public Settings | 0.484337 |
| appropriate protective measures | 0.466266 |
| higher risk | 0.529276 |
| limited human-to-human transmission | 0.485406 |
| pandemic M gene | 0.413886 |
| novel influenza virus | 0.676715 |
| flu-like symptoms | 0.41515 |
| personal protective equipment | 0.473229 |
| animal diagnostic laboratories | 0.508958 |
| similar youth development | 0.486234 |
| seasonal flu-related complications | 0.472164 |
| website fact sheet | 0.471472 |
| sick people | 0.427961 |
| state animal health | 0.523569 |
| H3N2v viruses | 0.54204 |
| people | 0.697656 |
| swine | 0.918866 |
| influenza testing | 0.511847 |
| influenza viruses | 0.722147 |
| virus.* Genetic testing | 0.50756 |
|
CLICK HERE |
| 7381 |
Centers for Disease Control and Prevention |
Html |
en |
Pandemic Resources Tools - FluLabSurge 1.0 |
FluLabSurge is a spreadsheet-based program designed to assist laboratory directors forecast demand for specimen testing during the next influenza pandemic (i.e., the surge in demand), and develop response plans - CDC |
| different modules | 0.504497 |
| clinical diagnostics | 0.522126 |
| laboratory directors | 0.520015 |
| United States | 0.495422 |
| influenza-testing laboratories | 0.41566 |
| strain identification | 0.417184 |
| Software Application | 0.519959 |
| free storage memory | 0.48972 |
| response plans | 0.422225 |
| one-page plan | 0.421335 |
| pandemic influenza | 0.742291 |
| one-way sensitivity analysis | 0.496166 |
| U.S. Federal Government | 0.486984 |
| testing capacity | 0.446881 |
| time period | 0.410813 |
| diagnostic machines | 0.412385 |
| particular module | 0.461101 |
| FluLabSurge download | 0.43845 |
| lab capacity | 0.422321 |
| 1918-type pandemic scenarios | 0.768625 |
| general modeling philosophy | 0.482558 |
| Cox NJ | 0.486651 |
| file download menu | 0.487674 |
| total number | 0.419412 |
|
| spreadsheet-based program | 0.429849 |
| Fukuda K. Modeling | 0.493421 |
| particular laboratory | 0.42249 |
| Fukuda K. | 0.513602 |
| influenza pandemic | 0.886691 |
| economic impact | 0.566602 |
| QuickStart Manual | 0.512333 |
| Pandemic Planning Module | 0.97658 |
| daily number | 0.528611 |
| Security Warning Screen | 0.480604 |
| Download Stand-alone FluLabSurge | 0.719888 |
| specimens | 0.427479 |
| additional test | 0.410827 |
| public health officials | 0.519504 |
| Meltzer MI | 0.588279 |
| Laboratory Capacity Module | 0.737219 |
| Workload Demand Module | 0.745783 |
| user-defined testing goals | 0.531666 |
| meaningful results | 0.415942 |
| page | 0.427012 |
| 1968-type pandemic | 0.672448 |
| laboratory testing capacities | 0.530887 |
| pandemic stages | 0.698113 |
|
CLICK HERE |
| 8268 |
Centers for Disease Control and Prevention |
Html |
en |
Vital Signs: Carbapenem-Resistant Enterobacteriaceae |
Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: mmwrq@cdc.gov. |
| Escherichia coli | 0.466345 |
| CRE HAI | 0.631009 |
| CRE emergence.* Patients | 0.624794 |
| CRE definitions | 0.610392 |
| U.S. acute-care hospitals | 0.475282 |
| Current CRE prevention | 0.622305 |
| Klebsiella species | 0.517705 |
| Enterobacteriaceae infections | 0.471007 |
| CRE burden | 0.593277 |
| Nosocomial Infection Surveillance | 0.504013 |
| surgical site infections | 0.466075 |
| substantial health-care exposures | 0.508069 |
| Klebsiella pneumoniae carbapenemase | 0.47937 |
| acute-care hospitals | 0.684702 |
| CRE | 0.926293 |
| Laboratory Standards Institute | 0.465443 |
| population-based CRE surveillance | 0.716057 |
| United States | 0.620626 |
| health-care–associated infections | 0.468467 |
| panresistant Klebsiella pneumoniae | 0.468596 |
| Emerging Infections Program | 0.506065 |
| CRE control efforts | 0.616337 |
| central-line–associated bloodstream infections | 0.468343 |
| EIP CRE surveillance | 0.641391 |
|
| Klebsiella oxytoca | 0.471968 |
| long-term acute-care hospitals | 0.544472 |
| National Healthcare Safety | 0.482458 |
| CRE episodes | 0.628771 |
| health-care settings | 0.50975 |
| CRE bloodstream infections | 0.623659 |
| health-care infections | 0.468808 |
| CRE gains | 0.582108 |
| CRE surveillance project | 0.713855 |
| CRE prevention strategies | 0.663682 |
| CRE incidence | 0.593682 |
| pan-resistant CRE | 0.599614 |
| short-stay acute-care hospitals | 0.505885 |
| gram-negative bacilli | 0.50432 |
| carbapenem resistance | 0.468966 |
| proportion CRE | 0.610677 |
| urinary tract infections | 0.46381 |
| health-care facilities | 0.46571 |
| CRE patients | 0.643311 |
| CRE culture-positive episodes | 0.746417 |
| Healthcare Safety Network | 0.529321 |
| past decade | 0.488091 |
| Klebsiella pneumoniae | 0.525158 |
| National Nosocomial Infection | 0.487718 |
|
CLICK HERE |
| 9037 |
Centers for Disease Control and Prevention |
Html |
en |
Notes from the Field: Occupationally Acquired Salmonella I4,12:i:1,2 Infection in a Phlebotomist - Minnesota, January2013 |
Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: mmwrq@cdc.gov. |
| mmwrq@cdc.gov. | 0.738302 |
| personal risk | 0.715438 |
| clinical cases | 0.725059 |
| identification band | 0.719885 |
| symptom onset | 0.744216 |
| Human Services | 0.791619 |
| Minnesota Department | 0.733629 |
| assistive technology | 0.732861 |
| infection prevention specialist | 0.853116 |
| MMWR HTML versions | 0.804563 |
| U.S. Department | 0.787503 |
| Kirk E. Smith | 0.803645 |
| phlebotomist | 0.722315 |
| electronic PDF version | 0.794114 |
| Salmonella transmission | 0.771137 |
| health-care workers | 0.846983 |
| personal protective equipment | 0.803078 |
| C. Patient | 0.747978 |
| Contact GPO | 0.73223 |
| infected patients | 0.738217 |
| Ginette Dobbins | 0.726259 |
| occupationally acquired infections | 0.809478 |
| commercial sources | 0.709454 |
| Illness onset dates | 0.849916 |
|
| Minnesota Dept | 0.712812 |
| frozen mice | 0.720471 |
| original paper copy | 0.798196 |
| Joni Scheftel | 0.713791 |
| hand-held sample tracking | 0.81983 |
| regular disinfection | 0.714244 |
| indistinguishable PFGE pattern | 0.848002 |
| multistate outbreak | 0.728515 |
| Mary J. Choi | 0.969555 |
| U.S. Government Printing | 0.804667 |
| original MMWR paper | 0.801582 |
| Minnesota resident | 0.719593 |
| indistinguishable pulsed-field gel | 0.859507 |
| frozen feeder mice | 0.819715 |
| MMWR readers | 0.716385 |
| MDH Public Health | 0.860793 |
| subject line | 0.731709 |
| typeset documents | 0.713517 |
| trade names | 0.709511 |
| temporal relationship | 0.714829 |
| occupationally acquired Salmonella | 0.876924 |
| risk factor | 0.713516 |
| Richard Danila | 0.711802 |
| occupational person-to-person contact | 0.818416 |
|
CLICK HERE |
| 9225 |
Centers for Disease Control and Prevention |
Html |
en |
Japanese Encephalitis Surveillance and Immunization - Asiaand the Western Pacific, 2012 |
Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: mmwrq@cdc.gov. |
| limited JE virus | 0.384675 |
| JE virus infection | 0.416332 |
| je laboratory network | 0.472324 |
| JE disease burden | 0.392449 |
| JE surveillance | 0.699199 |
| JE vaccine | 0.615196 |
| JE case | 0.456439 |
| Western Pacific Region | 0.213137 |
| JE immunization programs | 0.459832 |
| JE prevention activities | 0.389795 |
| JE risk | 0.380243 |
| JE immunization program | 0.595277 |
| national immunization programs | 0.203587 |
| effective JE prevention | 0.378277 |
| Susan L. Hills | 0.200043 |
| World Health Organization | 0.226498 |
| JE surveillance programs | 0.475501 |
| je prevention | 0.459887 |
|
| JE case reporting | 0.393241 |
| sentinel surveillance | 0.207298 |
| countries | 0.301468 |
| JE virus transmission | 0.975698 |
| JE control | 0.425094 |
| surveillance case definition | 0.22018 |
| surveillance sites | 0.208533 |
| JE vaccination program | 0.387209 |
| public health problem | 0.279711 |
| case definition | 0.253208 |
| government surveillance programs | 0.216907 |
| virus transmission risk | 0.493745 |
| risk areas | 0.200388 |
| JE vaccination | 0.400127 |
| laboratory confirmation | 0.207494 |
| JE cases | 0.482208 |
| pediatric JE vaccines | 0.447179 |
| Western Pacific | 0.241774 |
|
CLICK HERE |
| 14363 |
Centers for Disease Control and Prevention |
Html |
en |
Tobacco Use Among Middle and High School Students - UnitedStates, 2011-2015 | MMWR |
The Morbidity and Mortality Weekly Report (MMWR) Series is prepared by the Centers for Disease Control and Prevention (CDC). |
| current tobacco | 0.278894 |
| overall tobacco product | 0.243191 |
| Youth Tobacco Surveys | 0.234609 |
| electronic cigarettes | 0.303768 |
| Tobacco prevention | 0.2096 |
| tobacco control outcome | 0.232916 |
| tobacco product constituents | 0.243672 |
| conventional tobacco products | 0.241954 |
| tobacco | 0.985462 |
| dissolvable tobacco | 0.273311 |
| current tobacco product | 0.252738 |
| tobacco product types | 0.244873 |
| tobacco pipes | 0.202683 |
| tobacco product | 0.836433 |
| hookah tobacco | 0.207933 |
| middle school students | 0.413912 |
| comprehensive tobacco control | 0.34538 |
|
| cigars | 0.281741 |
| tobacco product prices | 0.233709 |
| certain tobacco products | 0.259352 |
| school current tobacco | 0.244035 |
| hookahs | 0.229507 |
| used tobacco product | 0.238552 |
| high school students | 0.802307 |
| tobacco pipe | 0.208321 |
| e-cigarettes | 0.299378 |
| tobacco control policies | 0.262442 |
| tobacco products | 0.572382 |
| smokeless tobacco | 0.680322 |
| single tobacco product | 0.226304 |
| commonly used tobacco | 0.369991 |
| pipe tobacco | 0.563999 |
| cigarettes | 0.372179 |
|
CLICK HERE |
| 15438 |
Centers for Disease Control and Prevention |
Html |
en |
Evaluation of the Impact of National HIV Testing Day -United States, 2011-2014 | MMWR |
The Morbidity and Mortality Weekly Report (MMWR) Series is prepared by the Centers for Disease Control and Prevention (CDC). |
| transgender persons | 0.262883 |
| CDC-funded HIV testing | 0.544156 |
| National HIV/AIDS Strategy | 0.368578 |
| HIV testing event | 0.44739 |
| single testing event | 0.278512 |
| NHTD | 0.440903 |
| number | 0.389754 |
| single conventional test | 0.295624 |
| HIV infections | 0.686895 |
| testing event data | 0.278872 |
| new HIV diagnoses | 0.434453 |
| individual HIV status | 0.385121 |
| mass testing campaigns | 0.269652 |
| HIV status | 0.541431 |
| new HIV diagnosis | 0.393337 |
| new HIV-positive test | 0.292037 |
| HIV testing campaigns | 0.4352 |
| new hiv-positive diagnoses | 0.546229 |
| racial/ethnic groups | 0.279763 |
| national testing event | 0.278523 |
| community-based testing events | 0.277038 |
| public health practice | 0.264293 |
| highest risk | 0.292448 |
| National HIV Prevention | 0.417219 |
| total testing events | 0.280687 |
|
| human immunodeficiency virus | 0.424037 |
| HIV test technology | 0.407125 |
| CDC-funded HIV tests | 0.387515 |
| CDC-funded testing events | 0.290754 |
| new hiv infections | 0.603405 |
| HIV testing events | 0.825814 |
| newly identified HIV | 0.553589 |
| United States | 0.298276 |
| HIV-positive persons | 0.363105 |
| national hiv testing | 0.505167 |
| total HIV testing | 0.413733 |
| significant increase | 0.259284 |
| National human immunodeficiency | 0.271734 |
| HIV-positive testing event | 0.303502 |
| HIV diagnosis | 0.408697 |
| valid HIV testing | 0.44929 |
| HIV test result | 0.404726 |
| HIV positive persons | 0.440229 |
| MSM | 0.268115 |
| hiv testing | 0.946508 |
| NHTD campaigns | 0.262485 |
| HIV | 0.971202 |
| target populations | 0.259144 |
| mass testing events | 0.276504 |
|
CLICK HERE |